TransMedics (NASDAQ: TMDX) investors approve directors, pay, stock plan and auditor
TransMedics Group, Inc. shareholders approved key proposals at their 2026 Annual Meeting, including the election of eight directors, the non-binding advisory compensation for named executive officers, and an amendment to the 2019 Stock Incentive Plan. Additionally, PricewaterhouseCoopers LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2026. These decisions reflect shareholder support for the company's governance and compensation strategies.
TransMedics (TMDX) officer receives RSU and stock option grants tied to service
TransMedics Group, Inc. officer Matthew S. Forsyth was granted 15,409 restricted stock units (RSUs) and a stock option for 23,171 shares on May 19, 2026. The stock option has an exercise price of $66.13 per share, expires on March 9, 2036, and vests progressively starting March 9, 2027, contingent on his continued service. These equity awards aim to align his compensation with the company's performance and increase his direct equity stake.
TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
TransMedics Group, Inc. has announced inducement grants of stock options and restricted stock units to 25 new employees. These grants were made outside the company's 2019 Stock Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4) and were approved by the Compensation Committee of TransMedics' Board of Directors. The grants are intended as an inducement material to the new employees entering into employment with the company.
TransMedics Group Inc (TMDX) Shares Fall 3.2% -- What GF Score of 75 Tells Investors
TransMedics Group Inc (TMDX) shares fell 3.2% to $66.13. The company has a GF Score of 75/100, indicating potential for higher long-term returns, primarily driven by strong growth prospects (10/10). Despite being undervalued by 58.9% according to its GF Value, concerns remain due to low financial strength (5/10) and profitability (4/10) scores, coupled with significant insider selling of $2.4 million over the past three months without any purchases.
TransMedics to Present at the William Blair 46th Annual Growth Stock Conference
TransMedics Group, Inc. (TMDX) announced it will participate in the upcoming William Blair 46th Annual Growth Stock Conference. The company's management will present on June 4, 2026, at 11:20 AM CT. A live webcast and replay of the presentation will be available on the investor relations section of TransMedics' website.
TransMedics to Present at the William Blair 46th Annual Growth Stock Conference
TransMedics Group, Inc. (Nasdaq: TMDX) announced its participation in the William Blair 46th Annual Growth Stock Conference in Chicago on June 2, 2026. The company's management team will present at 2:20 p.m. ET/1:20 p.m. CT, and a live webcast will be available on the Investors section of their website. TransMedics specializes in portable extracorporeal warm perfusion for organ transplantation.
TransMedics plans William Blair conference webcast for June 2
TransMedics (NASDAQ: TMDX) announced its participation in the William Blair 46th Annual Growth Stock Conference in Chicago on June 2, 2026. Management will present at 2:20 p.m. ET, with a live and archived webcast available on the company’s investor relations website. This presentation is part of TransMedics' ongoing investor outreach efforts, coming after recent volatile stock performance despite strong Q1 2026 revenue growth and strategic updates.
TransMedics Group, Inc. - Common Stock (NQ: TMDX
This article provides recent news headlines and analyst reports related to TransMedics Group, Inc. (TMDX) common stock. It includes a collection of articles from various financial news sources, detailing growth stock recommendations, earnings insights, analyst ratings, and market movements that impact TMDX. The sentiment of the headlines generally points towards positive growth prospects and analyst interest in the company.
Discipline and Rules-Based Execution in TMDX Response
This article provides an AI-driven analysis of Transmedics Group Inc. (NASDAQ: TMDX), highlighting weak near and mid-term sentiment and a neutral long-term outlook. It outlines three institutional trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop loss points. The analysis also includes multi-timeframe signal data and emphasizes the importance of disciplined, rules-based execution.
TransMedics Group (TMDX) price target decreased by 22.22% to 126.07
The price target for TransMedics Group (TMDX) has been decreased by 22.22%, bringing it down to $126.07. This adjustment reflects a significant change in the analysts' valuation of the company's stock.
TransMedics Group (TMDX) Drops 5.1% to $60.69
TransMedics Group (TMDX) shares dropped 5.1% to $60.69 on Wednesday, influenced by renewed attention to its valuation profile. The selloff occurred despite analysis from ChartMill positioning the stock as an example of "affordable growth" in medical technology, suggesting investor caution regarding valuation multiples in the sector. Investors are now watching for operational momentum to justify its valuation.
TransMedics Group (Nasdaq:TMDX) - Stock Analysis
TransMedics Group (TMDX) is a medical technology company focused on organ transplant therapy. The stock is currently trading at US$64.18, with analysts estimating a fair value of US$144.2, suggesting it is significantly undervalued. Recent news includes reaffirmed earnings guidance for FY2026, expansion into European transplant logistics with PAD Aviation, and updates on its clinical programs and new Controlled Hypothermic Organ Preservation System (CHOPS).
Earnings call transcript: TransMedics Q1 2026 earnings miss sends stock tumbling
TransMedics Group Inc. reported a significant earnings miss for Q1 2026, with EPS falling to $0.30 against a forecasted $0.62 and revenue slightly below expectations. This led to a sharp decline in the company's stock by 24.89% in after-hours trading. Despite near-term challenges and increased operating expenses, TransMedics maintains an optimistic outlook, driven by international expansion, innovative products like the CHOPS platform, and reiterated full-year revenue guidance.
Earnings call transcript: TransMedics Q1 2026 earnings miss sends stock tumbling
TransMedics Group Inc. reported an earnings and revenue miss for Q1 2026, with an EPS of $0.30 against a forecasted $0.62 and revenue of $173.9 million below the $174.47 million forecast. This led to a significant stock price drop, with shares plummeting 24.89% in after-hours trading. Despite the miss, the company highlights continued international expansion, new product innovations like the CHOPS platform, and reiterates its full-year 2026 revenue guidance of $727 million-$757 million, maintaining confidence in long-term growth.
Wall Street Zen Downgrades TransMedics Group (NASDAQ:TMDX) to Sell
Wall Street Zen downgraded TransMedics Group (NASDAQ:TMDX) to a "sell" rating following several other analysts lowering their outlooks and price targets. This comes after the medical device company missed Q1 EPS expectations, reporting $0.30 against an anticipated $0.62, despite a 21.2% year-over-year revenue increase. The stock currently trades near its 52-week low and below key moving averages, with recent insider transactions showing shares being sold.
TransMedics Group Drops 5.4% After Canaccord Genuity Maintains Buy
TransMedics Group (TMDX) shares dropped 5.4% after a wave of five analyst downgrades and price target cuts significantly reduced the consensus view on the medical device maker. Despite the price target reductions, four of the five firms maintained positive ratings, indicating a recalibration of short-term expectations rather than a complete loss of confidence. The market's reaction, evidenced by increased trading volume, suggests investors are pricing in additional risk beyond the analysts' revised models.
TransMedics Group, Inc. (NASDAQ:TMDX) Given Average Rating of "Moderate Buy" by Brokerages
TransMedics Group, Inc. (TMDX) has received an average "Moderate Buy" rating from twelve brokerages, with an average 12-month target price of $135.00, despite several recent target reductions and downgrades. The company's Q1 results showed a significant miss on EPS and contracting margins, leading to some analyst skepticism and a stock selloff. Insider selling has occurred, while institutional investors hold the vast majority of the stock.
TransMedics Group, Inc. (NASDAQ:TMDX) Q1 2026 Earnings Call Transcript
TransMedics Group, Inc. (TMDX) announced its Q1 2026 earnings, reporting $174 million in total revenue, a 21% year-over-year increase, despite missing earnings expectations with an EPS of $0.30 against an expected $0.62. The company reiterated its full-year 2026 revenue guidance of $727 million to $757 million, reflecting continued confidence in its growth strategy driven by OCS platform adoption and NOP services. Key initiatives include the development of the OCS Kidney platform, upgrading existing organ devices to Gen 3.0, and expanding its global footprint with the introduction of CHOPS for hypothermic organ preservation and the NOP Europe logistics network.
TransMedics Group (NASDAQ:TMDX) Given New $124.00 Price Target at Canaccord Genuity Group
Canaccord Genuity Group has revised its price target for TransMedics Group (NASDAQ:TMDX) down to $124.00 from $152.00, while maintaining a "buy" rating, indicating a potential 70.05% upside. This adjustment follows TransMedics' Q1 EPS miss and slightly below-consensus revenue, which led to a significant intraday stock drop. Analyst opinions are currently mixed, with some firms lowering targets due to margin concerns and an overall average target price of $135.00, alongside recent insider selling.
TransMedics Group Plunges 21.4% Amid Sector-Wide Selling
TransMedics Group's stock plunged 21.4% to $74.59 on Wednesday, significantly underperforming a sector-wide selloff in the medical device industry. This sharp decline, which saw its market capitalization reduced to $2.5 billion, was accompanied by heavy trading volume and a recent analyst price target cut. Investors are advised to monitor the situation for further developments or company-specific news.
Needham & Company LLC Has Lowered Expectations for TransMedics Group (NASDAQ:TMDX) Stock Price
Needham & Company LLC has reduced its price target for TransMedics Group (NASDAQ:TMDX) from $174 to $142, while reiterating a "buy" rating, indicating a potential upside of nearly 50%. This adjustment follows TransMedics missing Q1 EPS and slightly missing revenue, despite year-over-year revenue growth. The company currently holds a "Moderate Buy" consensus rating from analysts, with significant institutional ownership and recent insider stock sales.
Earnings call transcript: TransMedics Q1 2026 misses EPS forecast, stock stable
TransMedics (TMDX) reported Q1 2026 EPS of $0.30, significantly missing the forecast of $0.62, with revenue of $173.9 million also slightly below expectations. Despite the earnings miss, the stock rose 0.55% in aftermarket trading, indicating investor confidence in the company's strategic initiatives like CHOPS and OCS Kidney programs. Management highlighted robust revenue growth of 21% year-over-year and reiterated full-year 2026 revenue guidance, emphasizing long-term value creation through continued investments.
Transcript : TransMedics Group, Inc., Q1 2026 Earnings Call, May 05, 2026
This article provides the transcript of TransMedics Group, Inc.'s Q1 2026 Earnings Call held on May 5, 2026. The summary notes that TransMedics' Q1 adjusted earnings fell while revenue rose, leading to a post-hours decline in shares. The full transcript, provided by S&P Capital IQ, is reserved for subscribers.
TransMedics tumbles 22% on earnings miss despite revenue growth
TransMedics Group Inc. (NASDAQ:TMDX) shares fell 22% after reporting Q1 results that missed Wall Street earnings expectations, despite a 21% increase in revenue year-over-year. The medical technology company, specializing in organ transplant therapy, reiterated its strong full-year 2026 revenue guidance, exceeding analyst consensus. The company cited higher utilization of its Organ Care System as a key driver for revenue growth but noted a decline in gross margin and an increase in operating expenses due to investments and supply chain costs.
TransMedics (Nasdaq: TMDX) grows Q1 2026 revenue as margins tighten
TransMedics Group, Inc. reported a 21% increase in Q1 2026 revenue to $173.9 million, primarily driven by stronger adoption of its Organ Care System (OCS) for liver and heart transplants and growth in logistics services. Despite this top-line growth, the company experienced tighter margins and reduced profitability, with net income falling to $7.3 million from $25.7 million in the prior year, largely due to higher operating expenses and increased investments in research and development and infrastructure. TransMedics maintained its full-year 2026 revenue guidance of $727–$757 million, reflecting continued strategic growth initiatives including expanding its aviation fleet and advancing clinical programs.
TransMedics faces earnings test as jet fuel costs weigh
TransMedics Group Inc. is set to report its first-quarter earnings, facing scrutiny over its profitability amidst rising aviation fuel costs which impact its organ transport program. Analysts anticipate earnings of 62 cents per share on revenue of $174.47 million, and investors will look for commentary on how the company is managing fuel surcharges and its full-year guidance. The results will indicate if TransMedics can sustain its growth momentum despite a challenging cost environment and recent stock decline.
Hussman Strategic Advisors Inc. Acquires New Position in TransMedics Group, Inc. $TMDX
Hussman Strategic Advisors Inc. has acquired a new stake of 14,700 shares, valued at $1.79 million, in TransMedics Group, Inc. during the fourth quarter. This comes as institutional ownership in TMDX is high at 99.67%, while company insiders have been net sellers, disposing of over $2.35 million worth of shares recently. Analysts currently hold a "Moderate Buy" consensus rating with an average target price of $152.33 against the current trading price around $100.
TMDX SEC Filings - Transmedics Group 10-K, 10-Q, 8-K Forms
This page provides a comprehensive resource for Transmedics Group (TMDX) SEC filings, including 10-K, 10-Q, and 8-K reports, along with insider trading forms. It details how the company’s filings offer insights into its financial performance, risk management, and significant events related to its Organ Care System (OCS) and National OCS Program (NOP). The platform aids investors with AI-powered summaries, impact scoring, and sentiment analysis for these regulatory documents.
Rosen Law Firm Encourages TransMedics Group, Inc. Investors to Inquire About Securities Class Action Investigation - TMDX
The Rosen Law Firm is investigating potential securities claims against TransMedics Group, Inc. (NASDAQ: TMDX) on behalf of investors who may have been misled by the company's business information. This investigation follows a Scorpion Capital report alleging healthcare fraud and exploitation of terminally ill patients, which caused TransMedics' stock to fall significantly. The firm is preparing a class action lawsuit to recover investor losses and encourages affected shareholders to contact them.
Rosen Law Firm Encourages TransMedics Group, Inc. Investors to Inquire About Securities Class Action Investigation - TMDX
The Rosen Law Firm has announced an investigation into potential securities claims against TransMedics Group, Inc. (NASDAQ: TMDX). This follows a report by Scorpion Capital alleging the company engaged in "extreme and grotesque healthcare fraud" and corruption, leading to a significant drop in TransMedics' stock price. The firm is preparing a class action for investors who purchased TransMedics securities and may be entitled to compensation.
Vanguard holds 1.737M shares in TransMedics (NASDAQ: TMDX)
Vanguard Capital Management has reported a beneficial ownership of 1,737,137 shares in TransMedics Group Inc (NASDAQ: TMDX), representing a 5.06% stake in the company. The Schedule 13G filing indicates that Vanguard has sole dispositive power over all these shares and sole voting power over 258,985 shares. This filing, signed on April 30, 2026, reflects a passive institutional holding, suggesting an investment purpose rather than an intent to influence control.
Vanguard Portfolio Management holding 5.68% of TransMedics (NASDAQ: TMDX) in Schedule 13G
Vanguard Portfolio Management has disclosed a 5.68% stake in TransMedics Group Inc (NASDAQ: TMDX) according to a Schedule 13G SEC filing. This includes beneficial ownership of 1,949,420 shares of common stock, with sole voting power over 29,885 shares and sole dispositive power over all 1,949,420 shares. The filing, dated April 29, 2026, positions Vanguard as a significant institutional holder, reflecting a passive investment.
TransMedics Group Announces Intent to Create the First Dedicated European Transplant Logistics Network with Strategic Investment in PAD Aviation service GmbH
TransMedics Group, Inc. announced a strategic investment in PAD Aviation service GmbH to establish the first dedicated European transplant logistics network. This initiative aims to replicate TransMedics' U.S. National OCS Program (NOP) model in Europe, integrating air and ground logistics to support its OCS perfusion platform. The goal is to expand access to donor organs and increase transplant volumes for patients across the European Union.
Should You Be Adding TransMedics Group (NASDAQ:TMDX) To Your Watchlist Today?
The article evaluates TransMedics Group (NASDAQ:TMDX) as a potential investment by examining its financial performance, growth metrics, and insider ownership. It highlights the company's impressive revenue growth and profitability while also noting the positive sentiment from insiders due to increasing ownership. The piece suggests that these factors make TMDX an attractive stock for investors' watchlists.
TransMedics Group Announces Intent to Create the First Dedicated European Transplant Logistics Network with Strategic Investment in PAD Aviation service GmbH
TransMedics Group, Inc. announced a strategic investment in Germany-based PAD Aviation, a private aviation operator, to establish the first dedicated European transplant logistics network. This initiative aims to expand access to donor organs and increase transplant volumes across Europe by replicating TransMedics' successful U.S. National OCS Program (NOP) and logistics model. The investment will support the company's OCS™ perfusion platform and clinical services, with a focus on Italy and broader European expansion.
TransMedics targets dedicated Europe transplant flights for donor organs
TransMedics Group (Nasdaq: TMDX) announced a definitive agreement to invest in Germany-based PAD Aviation service GmbH to establish a dedicated European organ transplant logistics network. This strategic investment aims to replicate TransMedics' successful U.S. National OCS Program (NOP) model, supporting its OCS perfusion platform and clinical services to expand access to donor organs and increase transplant volumes across Europe. The transaction is expected to close later in 2026, subject to customary closing and regulatory conditions, with financial terms undisclosed.
TransMedics Group Announces Intent to Create the First Dedicated European Transplant Logistics Network with Strategic Investment in PAD Aviation service GmbH
TransMedics Group, Inc. has announced a definitive agreement to invest in PAD Aviation service GmbH, a German private aviation operator. This strategic investment aims to establish the first dedicated European transplant logistics network, mirroring TransMedics' successful U.S. National OCS Program model. The goal is to expand access to donor organs and increase transplant volumes across the European Union using TransMedics' OCS™ perfusion platform and integrated logistics.
TransMedics Group (TMDX) to Release Quarterly Earnings on Tuesday
TransMedics Group (NASDAQ:TMDX) is scheduled to release its Q1 2026 earnings after market close on Tuesday, May 5th, with analysts expecting $0.62 EPS and $174.47M in revenue. Recent insider transactions show a director and the CFO selling significant shares in March, reducing their positions. The stock currently trades at $101.43, and analysts hold a consensus "Moderate Buy" rating with an average target price of $152.33.
TransMedics Group (NasdaqGM:TMDX) Stock Forecast & Analyst Predictions
TransMedics Group (NasdaqGM:TMDX) is forecast to grow earnings by 5.8% and revenue by 15.3% annually, although EPS is expected to decline by 4.6% per year. Analyst sentiment shows a constructive tone, with price targets generally increasing due to strong Q4 results, updated guidance, and expansion into heart, lung, and kidney transplant programs. The company's future growth is linked to clinical trials, organ platform expansion, and international reach.
TransMedics to Provide Update on Ongoing Clinical Programs at the International Society of Heart and Lung Transplantation 2026 Annual Meeting
TransMedics Group, Inc. will present updates on its ongoing clinical programs at the International Society of Heart and Lung Transplantation 2026 Annual Meeting. The company plans to unveil its new Controlled Hypothermic Organ Preservation System (CHOPS), designed to facilitate enrollment in critical control arms of its OCS ENHANCE Heart Part B and OCS DENOVO Lung clinical trials. CHOPS offers a superior method for controlled cold storage of donor organs, aiming to broaden TransMedics' product offerings and generate robust clinical evidence for organ transplantation.
TransMedics Group Q4 2025 earnings preview
This article is a preview of TransMedics Group's Q4 2025 earnings. It does not contain detailed financial information or predictions, but sets the stage for an upcoming earnings report. The full content of the article is not available in this snippet.
Universal Beteiligungs und Servicegesellschaft mbH Has $11.25 Million Stock Position in TransMedics Group, Inc. $TMDX
Universal Beteiligungs und Servicegesellschaft mbH significantly increased its stake in TransMedics Group, Inc. by 41.5% in the fourth quarter, now holding 92,446 shares valued at $11.25 million. This comes as several brokers raised their price targets for TMDX, resulting in a "Moderate Buy" consensus rating and an average target price of $152.33. Meanwhile, company insiders have recently been net sellers of the stock.
Reasons to retain TransMedics stock in your portfolio for now
This article discusses the reasons to retain TransMedics stock in a portfolio. It likely covers aspects such as the company's financial performance, market position, and future growth prospects to justify its retention despite potential market fluctuations.
Is TransMedics’ New CHOPS Trial Control Device Reshaping The Investment Case For TransMedics Group (TMDX)?
TransMedics Group introduced its new Controlled Hypothermic Organ Preservation System (CHOPS) at the 2026 International Society of Heart and Lung Transplantation meeting. CHOPS is an FDA-regulated control device for the OCS ENHANCE Heart Part B and OCS DENOVO Lung trials, aiming to improve trial design and isolate the performance of TransMedics' perfusion platforms. This development is expected to strengthen the investment narrative by making future trial readouts more convincing to stakeholders, though investors should still consider the risks of underperformance.
(TMDX) Movement Within Algorithmic Entry Frameworks
This article from Stock Traders Daily outlines algorithmic entry frameworks for Transmedics Group Inc. (NASDAQ: TMDX), noting a neutral near-term sentiment but strong mid-term sentiment that may be stalling. It details three distinct AI-generated trading strategies—Position, Momentum Breakout, and Risk Hedging—along with multi-timeframe signal analysis, providing entry zones, targets, and stop-loss levels. The piece emphasizes the exceptional risk-reward setup targeting a 17.3% gain with minimal risk.
Analysts Offer Insights on Healthcare Companies: TransMedics Group (TMDX) and Boston Scientific (BSX)
Two analysts have offered bullish insights on healthcare companies TransMedics Group (TMDX) and Boston Scientific (BSX). Needham maintained a Buy rating on TransMedics Group with a $174.00 price target, while Mizuho Securities maintained a Buy rating on Boston Scientific. Both stocks show significant upside potential based on average price targets from analyst consensus ratings.
TransMedics puts new organ-cooling device into heart, lung trial plans
TransMedics unveiled its new Controlled Hypothermic Organ Preservation System (CHOPS) at ISHLT 2026, an active cooling device designed to provide stable cold storage for donor organs. The company plans to submit an IDE amendment to the FDA to use CHOPS as a control arm in its OCS ENHANCE Heart Part B and OCS DENOVO Lung clinical trials, which both received full IDE approval earlier this year. This move aims to expand TransMedics' product offerings and provide robust comparative data against static cold storage methods in heart and lung transplantation.
TransMedics will discuss first-quarter results after market close May 5
TransMedics (Nasdaq: TMDX) announced it will release its first-quarter 2026 financial results after market close on Tuesday, May 5, 2026. The management team will host a conference call at 4:30 p.m. ET to discuss the results, with dial-in and webcast details provided. This announcement continues the company's regular cadence of financial disclosures following strong 2025 performance.
TransMedics to Report First Quarter 2026 Financial Results on May 5, 2026
TransMedics Group, Inc. (Nasdaq: TMDX) announced its plans to release first-quarter 2026 financial results after market close on Tuesday, May 5, 2026. The company will host a conference call on the same day at 4:30 p.m. ET to discuss the results, with details provided for investors to participate. TransMedics specializes in medical technology for organ transplant therapy, addressing the need for better donor organs.
Organ Preservation Market to Reach USD 466.23 Million by 2033 at 8.6% CAGR; North America Leads with 45% Share - Key Players: XVIVO Perfusion AB, CryoLife, Inc., BioLife Solutions, Inc., TransMedics Group, OrganOx Limited
The global organ preservation market is projected to grow from USD 288.21 million in 2025 to USD 466.23 million by 2033, exhibiting an 8.6% CAGR, driven by increasing organ transplant procedures and technological advancements. North America currently leads the market with a 45% share. Key players in this evolving sector include XVIVO Perfusion AB, CryoLife, Inc., BioLife Solutions, Inc., TransMedics Group, and OrganOx Limited, focusing on innovations in perfusion and preservation solutions.
